Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives $25.80 Consensus Target Price from Brokerages

Key Points

• Stoke Therapeutics, Inc. has an average price target of $25.80 from brokerages, with five analysts rating it as a "buy" and two as a "strong buy."
• The company's stock performance shows a 52-week high of $16.15 and a low of $5.35, currently trading at $13.10 with a market capitalization of approximately $715.26 million.
• Significant institutional activities include GAMMA Investing LLC boosting its position by 1,842% in the 1st quarter, acquiring over 5,000 additional shares.

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) have received an average rating of "Buy" from the seven analysts that are currently covering the stock, Marketbeat reports. Five investment analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $25.80.

Several analysts have weighed in on STOK shares. HC Wainwright cut their price objective on Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating on the stock in a research report on Wednesday, May 14th. Cantor Fitzgerald raised Stoke Therapeutics to a "strong-buy" rating in a research report on Wednesday, May 14th. Jefferies Financial Group assumed coverage on Stoke Therapeutics in a research report on Friday, July 18th. They issued a "buy" rating and a $30.00 price target on the stock. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a research report on Tuesday, July 1st.

Insider Activity at Stoke Therapeutics

In related news, insider Barry Ticho sold 6,471 shares of the stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $10.03, for a total value of $64,904.13. Following the completion of the transaction, the insider owned 25,782 shares of the company's stock, valued at approximately $258,593.46. This trade represents a 20.06% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 9.50% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in STOK. Toronto Dominion Bank bought a new position in shares of Stoke Therapeutics in the 4th quarter valued at about $35,001,000. RTW Investments LP raised its position in Stoke Therapeutics by 10.1% in the 4th quarter. RTW Investments LP now owns 5,123,525 shares of the company's stock worth $56,512,000 after purchasing an additional 471,240 shares during the period. Checkpoint Capital L.P. raised its position in Stoke Therapeutics by 139.3% in the 1st quarter. Checkpoint Capital L.P. now owns 730,717 shares of the company's stock worth $4,859,000 after purchasing an additional 425,330 shares during the period. Erste Asset Management GmbH purchased a new stake in Stoke Therapeutics in the 1st quarter worth about $2,670,000. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in Stoke Therapeutics in the 1st quarter worth about $2,376,000.

Stoke Therapeutics Stock Down 2.0%

Shares of STOK traded down $0.27 during trading hours on Friday, hitting $12.84. The company had a trading volume of 203,716 shares, compared to its average volume of 791,128. Stoke Therapeutics has a 52-week low of $5.35 and a 52-week high of $16.15. The firm has a market cap of $700.79 million, a P/E ratio of 16.23 and a beta of 1.14. The stock's 50 day moving average price is $11.37 and its 200 day moving average price is $9.73.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.